Oriental Aromatics Ltd

- The company has already had multiple rounds of conversations about demand from RFQ customers for H1 2025. - The numbers for H1 2025 demand appear healthy based on these discussions. - Positive feedback and substantial interest have been shown by global distributors and spot customers, especially for hydrogenation products. - The onboarding of RFQ customers for the Vadodara Hydrogenation Plant is expected in H2 2025. - Overall, the sales forecast for the Speciality Aroma Ingredients division remains strong. - New product launches and existing customer growth contribute to a healthy order pipeline. - The company remains cautiously optimistic but confident about capturing a substantial share of the global market for new products, such as Evermoss from the Mahad Greenfield site.

- There is no specific mention of any current or planned fundraising through debt or equity in the transcript. - The company reported a net debt-to-equity ratio of 0.35 as of 30 September 2024, indicating a moderate debt level. - Discussions in the call focused on operational performance, expansions, and new product launches without reference to raising funds. - The company appears to be financing ongoing expansions like the Mahad Greenfield project and Vadodara hydrogenation plant from existing resources. - If there are any developments related to fundraising, the management stated they would inform the investor community accordingly.

- Commercial production started at the Greenfield site in Mahad, Maharashtra, in November 2024, dedicated to producing a specialty aroma ingredient called Evermoss. - Investment at Mahad includes substantial plot development and infrastructure, with around 50-55% of costs toward the plot and utility block; approximately ₹70-75 crores directly invested in the product. - Hydrogenation plant at Vadodara commissioned in July 2024, currently operating at about 30% capacity; onboarding of RFQ customers expected in H2 2025. - Future expansions beyond the current announced phase at Mahad are not decided yet; the company will update investors as applicable. - Total revenue from expansions (Vadodara hydrogenation, Mahad, process reengineering) expected to add ₹250-300 crores in the next 2-3 years. - Depreciation from the Mahad plant estimated at ₹5-6 crores per year from Q4 FY25.

- The company expects steady growth across all three verticals—fragrance and flavor, speciality aroma ingredients, and camphor—with the fragrance and flavor division growing through new customer acquisitions and product launches. - Hydrogenation plant at Vadodara is operating at about 30% capacity; onboarding of RFQ customers is expected in H2 FY25, which will support top-line growth. - Greenfield facility in Mahad commenced production in November 2024, focusing on specialty aroma ingredient Evermoss, expected to generate significant revenues—projected 160 to 200 crores from this molecule alone. - Combined expansions (Vadodara hydrogenation, Mahad Greenfield, process reengineering) may contribute an additional ₹250-300 crores in top line over the next 2-3 years. - Overall, growth of 5-10% is anticipated in existing businesses in H2 FY25, though camphor remains seasonal and demand will be monitored. - The company aims for a cautious but positive outlook in demand and revenue growth through product portfolio expansion and market penetration.

- The company expects steady demand growth across fragrance, flavor, and specialty aroma ingredients divisions, supported by new customer acquisitions and product launches. - EBITDA margin guidance is cautiously optimistic, maintaining a 10-12% range due to new plants and products stabilizing. - Expansion projects like the Vadodara hydrogenation plant and Mahad Greenfield site are expected to add ₹250-300 crores to top-line over the next 2-3 years. - Hydrogenation and specialty aroma ingredients are expected to offer healthy margins, contributing positively to overall profitability. - Camphor segment remains seasonal and price-volatile, which may impact margins intermittently. - Demand outlook for H1 2025 is robust, supporting positive earnings momentum. - The company aims to sustain double-digit EBITDA margins and improve profitability from current 12.08% quarterly margin and strong H1 FY25 performance. - Net profit for H1 FY25 improved significantly, signaling confidence in future earnings growth.